RxDoctor Payments Data

Timothy Malone, DO

General Practice · Dallas, TXNPI 1649205873

Payments from drug & device makers

$14,219in general payments, 2019–2025

Across 446 payments — averaging $31.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • Bayer$923
  • Corcept Therapeutics$901
  • plus $6K from 33 others

What the payments were for

  • Travel & lodging$3042%
  • Food & beverage$13,91498%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,219 in reported general payments places this provider in the 95th percentile of 8,074 general practice providers in Texas.

See all general practice providers in Texas

Medicare billing

Part B allowed, 2024
$18,507
Medicare patients
39
Services billed
345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide40$44,860
OzempicSemaglutide21$29,281
FarxigaDapagliflozin Propanediol13$11,948
EliquisApixaban12$11,446
JardianceEmpagliflozin12$7,137
Tramadol Hcl ErTramadol Hcl16$2,845
Levothyroxine Sodium86$1,039
Alprazolam100$763
Atorvastatin Calcium74$700
Bupropion XlBupropion Hcl40$635
Tamsulosin Hcl31$531
Albuterol Sulfate HfaAlbuterol Sulfate24$345
Gabapentin42$331
Losartan Potassium34$310
Rosuvastatin Calcium46$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,143$44,86040 claims
Novo NordiskOzempic$2,066$29,28121 claims
AstraZenecaFarxiga$2,074$11,94813 claims
PfizerEliquis$273$11,44612 claims
Boehringer IngelheimJardiance$15$7,13712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,074 general practice providers in Texas.

Other general practice in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →